Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSIP1 | O75475 | 2/20 | 0.52 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.46 |
| ▸ | IKBKB | O14920 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.39 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31192532 | 1.00 | PSIP1 (0.52) | PSIP1ENPP2IKBKBNPC1TNF | |
| SCHEMBL10066425 | 0.84 | PSIP1 (0.56) | PSIP1NPC1TNFRAB9ANOD1 | |
| SCHEMBL28266014 | 0.82 | PSIP1 (0.54) | PSIP1NPC1TNFRAB9ANOD1 | |
| SCHEMBL646928 | 0.82 | ALDH1A1 (0.50) | ENPP2IKBKBNPC1TNFRAB9A | |
| SCHEMBL8032806 | 0.82 | PTGES2 (0.42) | ENPP2IKBKBPTGES2PRSS1PRSS2 | |
| SCHEMBL17048453 | 0.82 | ADAMTS4 (0.41) | ENPP2IKBKBNPC1TNFRAB9A | |
| SCHEMBL17263850 | 0.81 | PSIP1 (0.68) | PSIP1NPC1RAB9ABRD4ALDH1A1 | |
| SCHEMBL23214313 | 0.81 | PSIP1 (0.52) | PSIP1NPC1TNFRAB9ANOD1 | |
| SCHEMBL2642741 | 0.81 | PSIP1 (0.66) | PSIP1ENPP2NPC1TNFRAB9A | |
| SCHEMBL10180981 | 0.81 | PSIP1 (0.52) | PSIP1NPC1TNFRAB9ANOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4692085-A2 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | Nxera Pharma UK Limited (GB) | 2026-02-11 | — | — | EP | disclosed |
| EP-4041388-B1 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2025-11-26 | — | — | EP | disclosed |
| US-12391641-B2 | Prostaglandin EP4 receptor antagonist compounds | Nxera Pharma UK Limitied (GB) | 2025-08-19 | — | — | US | disclosed |
| US-20220411364-A1 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2022-12-29 | — | — | US | disclosed |
| US-20220411364-A1 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2022-12-29 | — | — | US | disclosed |
| EP-4041388-A1 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | Heptares Therapeutics Limited (GB) | 2022-08-17 | — | — | EP | disclosed |
| CN-114585603-A | Prostaglandin EP4Receptor antagonist compounds | 赫普泰雅治疗有限公司 | 2022-06-03 | — | — | CN | disclosed |
| WO-2021069927-A1 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021069927-A1 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-04-15 | — | — | WO | disclosed |
| US-20210040062-A1 | AZOLE-SUBSTITUTED PYRIDINE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2021-02-11 | — | — | US | disclosed |
| WO-2017141927-A1 | AZOLE-SUBSTITUTED PYRIDINE COMPOUND | 大正製薬株式会社 | 2017-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12391641-B2 | Prostaglandin EP4 receptor antagonist compounds | PTGER1, PTGER4, PTGER2 | PSIP1 1880/4885ENPP2 122/4885IKBKB 1016/4885 |
| US-20210040062-A1 | AZOLE-SUBSTITUTED PYRIDINE COMPOUND | CYP2F1, CYP21A2, CYP11B1 | PSIP1 4326/4885ENPP2 2022/4885IKBKB 1082/4885 |
| US-20220411364-A1 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | PTGER1, PTGER4, PTGER2 | PSIP1 1880/4885ENPP2 122/4885IKBKB 1016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.